Navigation Links
2008 a Record Year for Gerresheimer
Date:4/29/2009

DUSSELDORF, Germany, April 29 /PRNewswire-FirstCall/ --

- Strong Focus on the Markets of Pharma & Life Science

- Annual General Meeting Passes Dividend of EUR0.40 per Share

The Annual General Meeting of Gerresheimer AG today passed an unchanged dividend of EUR0.40 per share following the record year in 2008.

The Company finished the financial year 2008 with record results. Gerresheimer achieved sales of EUR1.06 billion (prior year EUR957.7m) and operating results (adjusted EBITDA) of EUR206.4m (prior year EUR181.6m).

At the Annual General Meeting in Dusseldorf the CEO Dr. Axel Herberg summarized the highlights of the financial year 2008: "We have achieved record levels in terms of sales and earnings. Gerresheimer is on a good course and will show itself to be very robust even in times of crisis."

The shareholders approved the actions of the members of the Company's Supervisory Board and Management Board for the financial year 2008 and, as in the prior year, passed a dividend payment of EUR0.40 per share.

With share capital representation of 59.44% the Annual General Meeting passed the following resolutions:

ITEM 2: Appropriation of net earnings for the financial year 2008:

(99.99% of votes in favor)

ITEM 3: Approval of the actions of the Management Board members for the financial year 2008:

(100% of votes in favor)

ITEM 4: Approval of the actions of the Supervisory Board members for the financial year 2008:

(100% of votes in favor)

ITEM 5: Supplementary election to the Supervisory Board of Mr. Theodor Stuth, Auditor and Certified Tax Advisor, Neuss:

    (100% of votes in favor)
    ITEM 6: Election of the auditor for the financial year 2009:
    (99.99% of votes in favor)
    The speech is available onhttp://www.gerresheimer.com/en/press.html.
    About Gerresheimer

Gerresheimer employs around 10,000 people in 42 locations in Europe, America and Asia. In the financial year 2008, worldwide sales totalled EUR1.06bn. The product portfolio ranges from pharma­ceu­tical vials made of glass and plastic through to complex drug-delivery systems for the pharma & life science industry. These include sterile syringes, inhalers and other system-based approaches for safe dosage and application of medications. The Group enjoys a leading position in markets which are characterised by high technical and regulatory barriers.(WKN: 587300)

    Contact Press

    Burkhard Lingenberg
    Director Corporate Communication & Marketing
    Phone +49-211-6181-250
    Fax   +49-211-6181-241
    e-mail b.lingenberg@gerresheimer.com

    Contact Investor Relations

    Anke Linnartz
    Director Corporate Investor Relations
    Phone +49-211-6181-314
    Fax   +49-211-6181-121
    e-mail a.linnartz@gerresheimer.com


'/>"/>
SOURCE Gerresheimer AG
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Globus Medical Announces Record 2nd Quarter 2007 Results
2. BioSpace Draws Record Crowd to Chicago Life Science Career Fair
3. CardioDynamics Receives FDA 510(k) Clearance for Innovative Clinical Parameters and Electronic Medical Record Compatibility
4. Neptune Reports Year End Financial Results - Neptune Records 18% Sales Increase and 43% EBITDA Increase in Year End Results
5. Monsanto Sees Record Sales in Fiscal Year 2007; Seeds and Traits Business Contributes to Strong Fourth Quarter and Year-End Results
6. Thermo Fisher Scientific Reports Record Third Quarter Revenues and Adjusted EPS and Raises Full-Year Guidance
7. China Biologic Products Reports Record Third Quarter 2007 Results
8. KV Pharmaceutical Company Reports Record Revenues for Fiscal 2008 Second Quarter and Six Months on a Preliminary Basis
9. The Female Health Company Reports Record Profit for Both Fourth Quarter and Fiscal Year 2007
10. Signalife Receives FDA Clearance for OTC Non-Prescription Event Recorder Device
11. Protalix BioTherapeutics Sets Record Date for Annual Meeting of Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... ... The Greater Gift Initiative, Inc , (GGI) a Winston-Salem, NC 501(c)3 ... mission is to advance global health and highlight the greater good of clinical trial ... clinical trial volunteer. The vision of GGI is to serve as a philanthropic connector ...
(Date:2/23/2017)... DIEGO and SAN FRANCISCO ... a privately-held regenerative medicine company, and Beyond Type 1, ... with type 1 diabetes, today announced a grant from ... a functional cure for type 1 and other insulin-requiring ... ViaCyte has been developing innovative stem cell-derived cell replacement ...
(Date:2/22/2017)... ... 22, 2017 , ... Kernel , a human intelligence ... (KRS) clinical development program. KRS is a neurotechnology spin-out from the Massachusetts ... applications. The terms of the transaction were not disclosed. , It addition ...
(Date:2/22/2017)... 22, 2017 Scientists propose in Nature ... damage in Gaucher and maybe other lysosomal storage diseases ... costs than current therapies. An international research ... , which also included investigators from the University of ... data Feb. 22. The study was conducted in mouse ...
Breaking Biology Technology:
(Date:2/2/2017)... -- Central to its deep commitment to honor the ... Prize Foundation today announced the laureates of the ... in their respective fields of Life Sciences and ... recognized with the 2017 Japan Prize for original ... the advancement of science and technology, but also ...
(Date:1/31/2017)... Jan. 31, 2017  Spero Therapeutics, LLC, a ... the treatment of bacterial infections, today announced it ... candidates from Pro Bono Bio Ltd (PBB) to ... multi-drug resistant forms of Gram-negative bacteria.   The assets ... Ltd, a PBB group company. "The ...
(Date:1/26/2017)... 26, 2017  Crossmatch, a leading provider of security ... aimed at combatting fraud, waste and abuse in assistance ... the Action on Disaster Relief conference in ... UN agencies and foreign assistance organizations throughout ... abuse are a largely unacknowledged problem in the foreign ...
Breaking Biology News(10 mins):